Literature DB >> 25837304

Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.

Katarzyna Lepeta1, Leszek Kaczmarek2.   

Abstract

Recent findings implicate alterations in glutamate signaling, leading to aberrant synaptic plasticity, in schizophrenia. Matrix metalloproteinase-9 (MMP-9) has been shown to regulate glutamate receptors, be regulated by glutamate at excitatory synapses, and modulate physiological and morphological synaptic plasticity. By means of functional gene polymorphism, gene responsiveness to antipsychotics and blood plasma levels MMP-9 has recently been implicated in schizophrenia. This commentary critically reviews these findings based on the hypothesis that MMP-9 contributes to pathological synaptic plasticity in schizophrenia.
© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  extracellular matrix; glutamate; synaptic plasticity

Mesh:

Substances:

Year:  2015        PMID: 25837304      PMCID: PMC4535641          DOI: 10.1093/schbul/sbv036

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  67 in total

Review 1.  LTP and LTD: an embarrassment of riches.

Authors:  Robert C Malenka; Mark F Bear
Journal:  Neuron       Date:  2004-09-30       Impact factor: 17.173

Review 2.  Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models.

Authors:  Chi-Ying Lin; Akira Sawa; Hanna Jaaro-Peled
Journal:  Neurobiol Dis       Date:  2011-09-03       Impact factor: 5.996

3.  Maintenance of long-term potentiation in hippocampal mossy fiber-CA3 pathway requires fine-tuned MMP-9 proteolytic activity.

Authors:  Grzegorz Wiera; Grazyna Wozniak; Malgorzata Bajor; Leszek Kaczmarek; Jerzy W Mozrzymas
Journal:  Hippocampus       Date:  2013-04-05       Impact factor: 3.899

4.  Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus.

Authors:  Arek Szklarczyk; Joanna Lapinska; Marcin Rylski; Ronald D G McKay; Leszek Kaczmarek
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

5.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis.

Authors:  B Zhang; S Ye; S M Herrmann; P Eriksson; M de Maat; A Evans; D Arveiler; G Luc; F Cambien; A Hamsten; H Watkins; A M Henney
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

Review 6.  Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Kazuto Oya; Taro Kishi; Nakao Iwata
Journal:  Hum Psychopharmacol       Date:  2014-09       Impact factor: 1.672

7.  Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.

Authors:  Harpreet Sidhu; Lorraine E Dansie; Peter W Hickmott; Douglas W Ethell; Iryna M Ethell
Journal:  J Neurosci       Date:  2014-07-23       Impact factor: 6.167

8.  Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia.

Authors:  Janusz K Rybakowski; Maria Skibinska; Pawel Kapelski; Leszek Kaczmarek; Joanna Hauser
Journal:  Schizophr Res       Date:  2009-03-04       Impact factor: 4.939

9.  Subcellular localization of intercellular adhesion molecule-5 (telencephalin) in the visual cortex is not developmentally regulated in the absence of matrix metalloproteinase-9.

Authors:  Emily A Kelly; Marie-Eve Tremblay; Carl G Gahmberg; Li Tian; Ania K Majewska
Journal:  J Comp Neurol       Date:  2014-02-15       Impact factor: 3.215

10.  Transsynaptic signaling by activity-dependent cleavage of neuroligin-1.

Authors:  Rui T Peixoto; Portia A Kunz; Hyungbae Kwon; Angela M Mabb; Bernardo L Sabatini; Benjamin D Philpot; Michael D Ehlers
Journal:  Neuron       Date:  2012-10-17       Impact factor: 17.173

View more
  28 in total

Review 1.  Neurodevelopmental Perspectives on Wnt Signaling in Psychiatry.

Authors:  Kimberly A Mulligan; Benjamin N R Cheyette
Journal:  Mol Neuropsychiatry       Date:  2017-01-13

Review 2.  Potential drug targets and treatment of schizophrenia.

Authors:  Anil Kumar; Monu Yadav; Milind Parle; Sameer Dhingra; Dinesh K Dhull
Journal:  Inflammopharmacology       Date:  2017-03-28       Impact factor: 4.473

Review 3.  The ELAV family of RNA-binding proteins in synaptic plasticity and long-term memory.

Authors:  Anastasios A Mirisis; Thomas J Carew
Journal:  Neurobiol Learn Mem       Date:  2019-04-15       Impact factor: 2.877

4.  Blood assessment of the expression levels of matrix metalloproteinase 9 (MMP9) and its natural inhibitor, TIMP1 genes in Iranian schizophrenic patients.

Authors:  Shahrzad Rahimi; Arezou Sayad; Elham Moslemi; Soudeh Ghafouri-Fard; Mohammad Taheri
Journal:  Metab Brain Dis       Date:  2017-06-04       Impact factor: 3.584

5.  Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.

Authors:  Krutika Deshpande; Vahan Martirosian; Brooke Naomi Nakamura; Mukund Iyer; Alex Julian; Rachel Eisenbarth; Ling Shao; Frank Attenello; Josh Neman
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

Review 6.  Weaving a Net of Neurobiological Mechanisms in Schizophrenia and Unraveling the Underlying Pathophysiology.

Authors:  Byron K Y Bitanihirwe; Sarah A Mauney; Tsung-Ung W Woo
Journal:  Biol Psychiatry       Date:  2016-03-09       Impact factor: 13.382

7.  Secreted tissue inhibitor of matrix metalloproteinase restricts trans-synaptic signaling to coordinate synaptogenesis.

Authors:  Jarrod Shilts; Kendal Broadie
Journal:  J Cell Sci       Date:  2017-06-02       Impact factor: 5.285

8.  The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.

Authors:  Johanna Seitz-Holland; Magdalena Seethaler; Nikos Makris; Jarrett Rushmore; Kang-Ik K Cho; Elizabeth Rizzoni; Mark Vangel; Olcay Senay Sahin; Carina Heller; Ofer Pasternak; Filip Szczepankiewicz; Carl-Fredrik Westin; Jan Lošák; Libor Ustohal; Josef Tomandl; Lubomír Vojtíšek; Petr Kudlička; Martin Jáni; T Wilson Woo; Tomáš Kašpárek; Zora Kikinis; Marek Kubicki
Journal:  Neuropsychopharmacology       Date:  2021-04-08       Impact factor: 7.853

9.  Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis.

Authors:  Georgios Schoretsanitis; Renato de Filippis; Maria Ntogka; Stefan Leucht; Christoph U Correll; John M Kane
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

10.  MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).

Authors:  Dominik Strzelecki; Olga Kałużyńska; Justyna Szyburska; Adam Wysokiński
Journal:  Int J Mol Sci       Date:  2016-07-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.